• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > About > Annual reports > Annual Report 2022

2022 Latin America highlights

My son was tested for Chagas disease and it took three months to receive the result, which was positive. He had to go to Santiago del Estero to receive treatment and it is difficult to travel from our village to the treatment centre.​

Rita Alejandra, also a Chagas patient, is pictured at home with her son and partner in Vaca Muerta, Argentina. 
The costly trip to the closest city to receive treatment takes one and a half hours.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Accelerating access to testing and treatment for Chagas disease
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Chagas disease affects millions of people in Latin America. But while the tools exist to save lives, the disease often goes undiagnosed, and those infected may not exhibit symptoms for years. A lack of awareness and knowledge of Chagas among healthcare professionals and the public alike leads to life-threatening delays in diagnosis and treatment.

Alongside our efforts to discover and develop improved treatments for Chagas, DNDi teams in Latin America are working to help boost access to testing and treatment in communities most affected by the disease. Together with our partners, we provided comprehensive training on Chagas diagnosis and clinical management to more than 1,000 health professionals in 2022 and donated essential laboratory equipment to bolster diagnostic and treatment monitoring services.

In Colombia, DNDi supported the introduction of a new diagnostic and treatment centre for Chagas in the municipality of Cubará. In Guatemala, our teams worked with the Ministry of Health to establish a diagnostic laboratory in Jalapa, where we donated equipment for processing diagnostic tests and introduced DNDi’s iChagas mobile app as a strategy to ensure continuing education following a programme of theoretical and hands-on training for health professionals at the facility. Improving care for pregnant women and infants is a major focus of our teams in Latin America, including work to improve routine Chagas screening at the primary healthcare level and prevent mother-to-child transmission of the disease. These efforts contribute to the Pan American Health Organization’s EMTCT Plus strategy, which aims to eliminate mother-to-child transmission of HIV, syphilis, hepatitis B, and Chagas disease.

Committed to eliminating Chagas: the Bogotá Manifesto

On 23 September 2022, the Chagas Disease Clinical Research Platform and the Global Chagas Coalition released the Bogotá Manifesto – setting out priorities for action and calling for intensified efforts to eliminate Chagas as a public health problem.

A joint effort of the scientific community, health programme managers, specialists, and people affected by the disease, the manifesto calls for six commitments from governments and organizations working against Chagas:

1. Improve access to diagnosis, treatment, and comprehensive care for people affected by Chagas;

2. Encourage investment in research and development for simpler, safer diagnostic and therapeutic tools;

3. Improve disease surveillance and control;

4. Strengthen access to training and information resources for healthcare workers and people living with Chagas;

5. Promote coordination among professionals, providing comprehensive care and guaranteeing the participation of people living with Chagas in strategies adapted to their needs; and

6. Continue to support activities related to World Chagas Day to highlight global efforts to reduce the impact of Chagas and promote actions to improve access to comprehensive care.

Jorge is a fruit farmer living with CL near Santa Fe de Antioquia, Colombia. For several months, Jorge was misdiagnosed but eventually started receiving the correct treatment. He struggles to access medical care, living outside a major urban area, and has to travel long distances to reach his treatment centre.

Cutaneous leishmaniasis: Advocating for simpler diagnostic tools

When Jorge Hernández, a fruit farmer in rural Antioquia, Colombia, developed a sore on his arm that would not heal, he became concerned. It took seven months and several lengthy journeys to doctors in the city for him to be correctly diagnosed with cutaneous leishmaniasis (CL) and receive treatment. Unfortunately, cases like Jorge’s are not uncommon – in part because simple diagnostic tests for CL do not exist.

In August 2022, during the WorldLeish7 conference in Colombia, the redeLEISH Network, a platform coordinated by DNDi that brings together specialists in CL from across Latin America, launched a manifesto calling for investment in R&D for simpler and more effective diagnostic tools for CL. The manifesto also urges the scientific community, governments, and funding agencies to coordinate their efforts and define a strategic agenda to enable the development and implementation of rapid tests and access to treatment for people affected by CL.

Garnering hundreds of online signatures following its release at tropical medicine conferences in Brazil and Colombia in 2022, the manifesto has gained significant traction. To amplify its impact, a redeLEISH working group is now developing strategies to increase commitment to the manifesto, including through champions in Latin American countries, and to convert support for the manifesto into funding for R&D and policy advocacy for CL diagnostics.

BACK TO 2022 ANNUAL REPORT

Photo credits: Ana Ferreira-DNDi; Sydelle Willow Smith-DNDi

Stay connected

Get our latest news, personal stories, research articles, and job opportunities.

DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
This website uses necessary cookies to function. If you give your consent, we will also use statistical, functional, and marketing cookies. See Cookie Policy.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo